 Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc NASDAQ: EGRX and Fennec Pharmaceuticals Inc NASDAQ: FENC received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Incs NASDAQ: ETON eye inflammation drug hadnt come by the Aug. 10 decision date.The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals.Here are the key catalysts for the unfolding week.ConferencesVirtual Keystone Symposia: Advances in Cancer Immunotherapy: Aug. 17-19PDUFA DatesGilead Sciences, Inc. NASDAQ: GILD and licensing partner GALAPAGOS NVS ADR NASDAQ: GLPG await FDA decision on the NDA for filgotinib in moderate-to-severe rheumatoid arthritis. estimated date of Wednesday, Aug. 19, assuming priority reviewThe FDA is set to rule on BioMarin Pharmaceutical Inc.s NASDAQ: BMRN BLA for valoctocogene roxaparvovec, its investigational AAV5 gene therapy for treating adults with hemophilia A. FridayTricida Inc NASDAQ: TCDA has a Aug. 22 PDUFA date for the NDA for its TRC 101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease. With FDAs communication to the company in mid-July, stating that it has identified deficiencies in the application, it is less likely the investigational drug is approved by the D-day. SaturdaySee also: Genoskin Offers Live Skin Models To Bridge Animal, Human Testing: The Market Opportunity Is HugeView more earnings on IBBEarningsMonday Milestone Scientific Inc. NYSE: MLSS before the market open China Biologic Products Holdings Inc NASDAQ: CBPO after the close Precipio Inc NASDAQ: PRPO after the closeTuesday ADC Therapeutics SA NYSE: ADCT before the market open PAVmed Inc NASDAQ: PAVM after the close Supernus Pharmaceuticals Inc NASDAQ: SUPN after the closeIPOsLa Jolla, California-based InhibRx, a clinical-stage biotechnology company with a pipeline of novel biologic therapeutic candidates, with particular focus on oncology, has filed with the SEC to offer 6 million shares of its common stock at an estimated price range of 16-18. The company said in the filing it has applied to list its shares on the Nasdaq under the ticker symbol INBX.Harmony Biosciences Holdings Inc, a Plymouth, Pennsylvania-based commercial-stage pharmaceutical company focused on innovative therapies for patients living with rare neurological disorders, has filed with the SEC to offer 4.651 million shares of its common stock. The estimated price range for the offering is 20-23. The company has applied for listing its shares on the Nasdaq under the ticker symbol HRMY.IPO Quiet Period ExpiryNurix Therapeutics Inc NASDAQ: NRIX iTeos Therapeutics Inc NASDAQ: ITOS Inozyme Pharma Inc NASDAQ: INZY Annexon Inc NASDAQ: ANNXRelated Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimers Trial, Modernas Vaccine Deal With US, Cellular Biomedicine To Go PrivateC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 